Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range…
Read More
Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ:…
Read More
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric's drug candidate library CAMBRIDGE, Mass. - Enveric…
Read More
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric's drug candidate library CAMBRIDGE, Mass. - Enveric…
Read More
In vitro pharmacology studies confirmed EB-003's ability to target desired serotonergic receptors, supporting the potential of the neuroplastogenic therapeutic candidate to address difficult-to-treat mental health disorders without inducing hallucinations Analysis…
Read More
Selection of EB-003 based on research indicating its non-hallucinogenic, anxiolytic and anti-depressant properties CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
Presentation showcases the profile of EB-003, a non-hallucinogenic, neuroplastogenic DMT analog, which has shown positive outcomes in animal models of anxiety and depression CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB)…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D.,…
Read More
Enveric and Aries recently announced a Licensing Agreement for patented topical product aimed at treating radiation dermatitis, which impacts approximately two million cancer patients per year and has a market…
Read More
Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disorders Announced preclinical results confirming oral bioavailability and significant brain exposure…
Read More
